Ziconotide
| Clinical data | |
|---|---|
| Pronunciation | /zaɪˈkɒnoʊtaɪd/ zy-KON-oh-tyd |
| Trade names | Prialt |
| Other names | SNX–111 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intrathecal |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Elimination half-life | 2.9–6.5 hours |
| Excretion | <1% urine |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.212.174 |
| Chemical and physical data | |
| Formula | C102H172N36O32S7 |
| Molar mass | 2639.14 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Ziconotide, sold under the brand name Prialt, also called intrathecal ziconotide (ITZ) because of its administration route, is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus, a cone snail, it is the synthetic form of an ω-conotoxin peptide.
In December 2004 the US Food and Drug Administration (FDA) approved ziconotide when delivered as an infusion into the cerebrospinal fluid using an intrathecal pump system.